SCHEMBL17935693

SCHEMBL17935693

CCOc1ccc(-c2nc3c(N)ncnc3n2CC2CCOC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 5/20 0.47
ADORA2A P29274 5/20 0.47
ADORA2B P29275 5/20 0.47
ADORA1 P30542 5/20 0.47
PIK3CD O00329 1/20 0.43
TLR7 Q9NYK1 2/20 0.42
LCK P06239 5/20 0.41
KCNH2 Q12809 3/20 0.41
ABL1 P00519 2/20 0.41
FBP1 P09467 2/20 0.41
CSK P41240 1/20 0.40
PIK3CA P42336 1/20 0.40
FYN P06241 1/20 0.40
RET P07949 1/20 0.40
PDGFRB P09619 1/20 0.40
PDGFRA P16234 1/20 0.40
FLT1 P17948 1/20 0.40
LTK P29376 1/20 0.40
KDR P35968 1/20 0.40
MAP2K2 P36507 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17935694 0.89 ADORA3 (0.54) ADORA3ADORA2AADORA2BADORA1PIK3CD
SCHEMBL17935695 0.87 ADORA3 (0.52) ADORA3ADORA2AADORA2BADORA1PIK3CD
SCHEMBL23620924 0.83 TLR7 (0.44) ADORA3ADORA2AADORA2BADORA1TLR7
SCHEMBL17935591 0.75 ADORA2A (0.55) ADORA3ADORA2AADORA2BADORA1PIK3CD
SCHEMBL23621142 0.70 ADORA2A (0.49) ADORA3ADORA2AADORA2BADORA1LCK
SCHEMBL23621027 0.68 ADORA2A (0.47) ADORA3ADORA2AADORA2BADORA1LCK
SCHEMBL12940530 0.66 NSD3 (0.58) ADORA3ADORA2AADORA2BADORA1
SCHEMBL4055632 0.66 ADORA2A (1.00) ADORA3ADORA2AADORA2BADORA1FBP1
SCHEMBL2195761 0.64 TLR7 (0.55) TLR7
SCHEMBL4054762 0.64 ADORA2A (1.00) ADORA3ADORA2AADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210361660-A1 SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-11-25 US disclosed
US-20190169190-A1 SMALL MOLECULES FOR THE TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-06-06 US disclosed
US-20180009809-A1 SMALL MOLECULES FOR THE TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-01-11 US disclosed
WO-2016115487-A1 SMALL MOLECULES FOR THE TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS JIANG JEAN X (US) 2016-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210361660-A1 SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS P2RY2, P2RY1, P2RX2 ADORA3 16/4885ADORA2A 4/4885ADORA2B 17/4885
US-20190169190-A1 SMALL MOLECULES FOR THE TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS ADORA2A, ADORA1, ADORA3 ADORA3 3/4885ADORA2A 1/4885ADORA2B 4/4885
US-20180009809-A1 SMALL MOLECULES FOR THE TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS ADORA2A, ADORA1, ADORA3 ADORA3 3/4885ADORA2A 1/4885ADORA2B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.